LLYEli Lilly and CompanyRunning, no new patients
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms
Neoplasms, Hematologic
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Mar 2015, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 2
- Patients
- 110 (planned)
- Started
- May 22, 2012
- Main results expected
- Mar 20, 2015
- Fully finished
- Dec 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants with an Objective Response (Objective Response Rate)
Measured over: Baseline until Disease Progression (PD) or Participant Stops Study (Estimated up to 24 Months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2015-03-20, no fading
Raw record changes
- none yet
Trial ID NCT01594723 · record last updated 2026-06-23 · checked 2026-11-09 15:36 UTC